- Home
- SGML vs SDGR Comparison
SGML vs SDGR Comparison
Compare SGML & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGML | SDGR |
|---|---|---|
| Founded | 2011 | 1990 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.3B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGML | SDGR |
|---|---|---|
| Price | $11.19 | $18.06 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 7 |
| Target Price | $13.00 | ★ $26.57 |
| AVG Volume (30 Days) | ★ 9.7M | 813.3K |
| Earning Date | 11-14-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $138,959,151.00 | ★ $256,951,000.00 |
| Revenue This Year | $52.45 | $23.69 |
| Revenue Next Year | $22.13 | $20.46 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 32.90 |
| 52 Week Low | $4.25 | $15.99 |
| 52 Week High | $13.40 | $28.47 |
Technical Indicators
Market Signals| Indicator | SGML | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 61.22 | 50.16 |
| Support Level | $9.37 | $17.53 |
| Resistance Level | $12.36 | $18.28 |
| Average True Range (ATR) | 1.24 | 0.66 |
| MACD | 0.04 | 0.20 |
| Stochastic Oscillator | 63.15 | 66.25 |
Price Performance
Historical ComparisonAbout SGML Sigma Lithium Corporation
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds a 100% interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.